PAP
MNPR icon

Persistent Asset Partners’s Monopar Therapeutics MNPR Stock Holding History

Persistent Asset Partners’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Buy
1,271
+488
+62% +$30.2K 0.04% 268
2026
Q1 		$42.9K Buy
+783
New +$47.3K 0.02% 263

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Persistent Asset Partners's MNPR Position: Q2 2026 in Review

Persistent Asset Partners increased its Monopar Therapeutics (MNPR) stake by 62% in Q2 2026, buying an estimated $30.2K and bringing the position to 1,271 shares worth $118K. The position accounts for 0.04% of the portfolio, ranked #268.

Persistent Asset Partners first reported a position in MNPR in Q1 2026 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Persistent Asset Partners held 1,271 shares of Monopar Therapeutics worth $118K as of Q2 2026.
  • Persistent Asset Partners bought 488 Monopar Therapeutics shares in Q2 2026, an estimated $30.2K.
  • Monopar Therapeutics made up 0.04% of Persistent Asset Partners's portfolio in Q2 2026, its #268 holding.
  • Persistent Asset Partners first reported a position in Monopar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.